Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 4 ans
Comparison Amphotericin B Liposome Neutropenic Pediatric Patients
To estimate in pediatric patients, aged 2 to 17 years, with persistent fever and neutropenia, the proportion of patients treated with caspofungin reporting one or more clinical and/or laboratory drug-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
To compare Progression Free Survival (PFS) using RECIST 1.1 as assessed by (Blinded Independent Central Review) BICR and Overall Survival (OS) in PD-L1 positive subjects and all subjects with advanced...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Serono International SA
MAJ Il y a 4 ans
A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subjects with Active Disease
Evaluate the safety and tolerability of oral cladribine (cladribine tablets)when added on to Rebif. Evaluate the efficacy of oral cladribine (cladribine tablets) when added on to Rebif compared to pla...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck KGaA
MAJ Il y a 4 ans
Safety and Efficacy study of M2951 in Subjects with Rheumatoid Arthritis
To assess the efficacy of M2951 in subjects with active RA on stable MTX therapy, as measured by the American College of Rheumatology (ACR) 20% (ACR20) response rate over a duration of 84 days.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck KGaA
MAJ Il y a 4 ans
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)
Phase Ib To determine the RP2D of tepotinib when used in combination with gefitinib (at the approved standard dose of 250 mg) when administered orally once daily over a 21-day cycle in subjects wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Farma y Química, S.A
MAJ Il y a 4 ans
An exploratory pharmacogenomic study of cetuximab monotherapy in patients with metastatic EGFR-Positive colorectal carcinoma
To explore whether Muc 2, Muc 3, CFTR, SERPINB-5, BMP-2, BTC, TLN2, EPHA1, HMGCoA or Spondin expression can predict response to CETUXIMAB treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) compared with the addition of a licensed drug (Glimepiride) in patients with Type 2 Diabetes
After 54 weeks, to assess the A1C-lowering efficacy of MK-3102 compared to glimepiride. To assess the safety and tolerability of MK-3102.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck & Co., Inc
MAJ Il y a 4 ans
A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
To assess HbA1c after 24 weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
A Clinical Trial to Test Different Doses of MK-5172 administered with Other Hepatitis C Virus Treatments
(1) To evaluate the efficacy of each treatment arm of MK-5172 in combination with peg-IFN and RBV as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp
MAJ Il y a 4 ans
Phase III study of efficacy, safety and tolerability of two human monoclonal antibodies to Clostridium Difficile toxin A and B, in patients receiving antibiotic therapy. Studio di fase III per valutare l'efficacia, la sicurezza e la tollerabilita' di due anticorpi monoclonali umani verso le tossine A e B del batterio Clostridium Difficile, in pazienti in trattamento con terapia antibiotica
assess whether MK-3415A given with the standard of care antibacterial therapy (SOC) relative to MK-3415, MK-6072, and placebo given with SOC reduces CDI recurrence over a period of 12 weeks and to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant